Country: Canada
Language: English
Source: Health Canada
CHROMIUM (CHROMIC CHLORIDE); ZINC (ZINC SULFATE); COPPER (CUPRIC SULFATE); MANGANESE (MANGANESE SULFATE)
SANDOZ CANADA INCORPORATED
B05XA31
ELECTROLYTES IN COMB WITH OTHER DRUGS
4MCG; 1MG; .4MG; .1MG
LIQUID
CHROMIUM (CHROMIC CHLORIDE) 4MCG; ZINC (ZINC SULFATE) 1MG; COPPER (CUPRIC SULFATE) .4MG; MANGANESE (MANGANESE SULFATE) .1MG
INTRAVENOUS
10X5ML VIAL
Ethical
REPLACEMENT PREPARATIONS
Active ingredient group (AIG) number: 0414689003; AHFS:
APPROVED
2006-06-07
_MICRO +4 REGULAR STRENGTH (4 Trace Elements Injection USP) _ _Page 1 of 17 _ _ _ _ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION MICRO +4 REGULAR STRENGTH 4 Trace Elements Injection Zinc, 1 mg/mL Copper, 0.4 mg/mL Manganese, 0.1 mg/mL Chromium, 4 mcg/mL USP Intravenous Combination of Electrolytes Sandoz Canada Inc. 110 Rue de Lauzon Boucherville, (Québec), Canada J4B 1K6 Date of Preparation: APR 25, 1994 Date of Revision: JAN 19, 2022 Control No.: 250301 _MICRO +4 REGULAR STRENGTH (4 Trace Elements Injection USP) _ _Page 2 of 17 _ RECENT MAJOR LABEL CHANGES 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment (Pediatrics) 01/2022 7 WARNINGS AND PRECAUTIONS, General 01/2022 TABLE OF CONTENTS Sections and Subsections that are not applicable at the time of authorization are not listed. PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS..................................................................................................................... 4 1.1 P EDIATRICS ( ≤ 18 YEARS OF AGE ) ..................................................................................... 4 1.2 G ERIATRICS (≥ 65 YEARS OF AGE ) ..................................................................................... 4 2 CONTRAINDICATIONS ....................................................................................................... 4 4 DOSAGE AND ADMINISTRATION........................................................................................ 4 4.1 D OSING C ONSIDERATIONS ..................................................................................................... 4 4.2 R ECOMMENDED D OSE AND D OSAGE A DJUSTMENT ...................................................................... 5 4.3 R ECONSTITUTION ................................................................................................................. 6 4.4 A DMINISTRATION ................................................................ Read the complete document